Unity Biotechnology is built around senescent cells: cells that have stopped dividing but don't die off, instead accumulating with age and secreting inflammatory signals that damage surrounding tissue. Senolytics are compounds designed to selectively clear those cells. Unity was among the earliest companies to move this idea out of animal studies and into human clinical trials, giving it a longer public track record than most names in this directory, including both the credibility of being public and the scrutiny that comes with disclosed trial results.
That clinical-stage status is the key distinction from earlier-stage, privately-held peers like Altos Labs or Retro Biosciences: Unity's programs have had to clear regulatory and efficacy bars that basic-research-stage companies haven't yet faced. Progress in senolytics generally has been genuinely promising in animal models but mixed and slower than early hype suggested once it reached human trials, a pattern worth keeping in mind when reading company communications versus peer-reviewed trial data.
For the underlying science in more depth, see the senolytics entry in the therapies directory and the companion article on senolytics, which covers the mechanism, evidence level, and the researchers (Judith Campisi, James Kirkland) most associated with the field.